QIAGEN NV

2026 May — Q1 2026 results and guidance cut; QuantiFERON outlook lowered

QIAGEN reported Q1 2026 results and updated full-year guidance, cutting FY 2026 net-sales growth outlook from "at least 5% CER" to "about 1–2% CER" and saying QuantiFERON full-year sales were now expected to be unchanged versus 2025. Market perception shifted from expecting a return to stronger growth toward recognition of persistent headwinds: weaker immigration-testing demand for QuantiFERON, caution among U.S. life-science customers and geopolitical uncertainty. Investors treated the company as operating in a slower-growth, more cyclical end-market with specific product headwinds rather than as a fast re-acceleration story. QIAGEN reaffirmed QuantiFERON full-year 2026 sales to be unchanged at CER versus 2025 sales of $503 million and updated FY 2026 net sales growth to about 1–2% CER (previously at least 5% CER) [8][13][10].

2026 Mar–Nov (announced Nov 4, 2025; ongoing into 2026) — CEO succession announced (Thierry Bernard to step down)

QIAGEN announced Thierry Bernard will step down as CEO and Managing Director once a successor is appointed; Bernard said he would not stand for re-election at the AGM planned for June 2026 and would remain in role until a successor is named. The leadership change prompted investors to reassess execution risk and strategic continuity after several years of portfolio reshaping and margin initiatives. Some viewed a planned CEO transition as an opportunity for renewed strategic clarity around capital allocation, divestitures, and potential M&A or monetisation of noncore assets. Corporate announcement published by QIAGEN (CEO transition notice) [4].

2025 Nov–Dec / 2025 (mid-2025 actions announced) — Shareholder measures and balance-sheet actions (dividend initiation and repurchase program)

After solid Q1 2025 results, QIAGEN sought shareholder approval to initiate a dividend and announced a new €500 million share repurchase program. Investors interpreted the move as management signalling confidence in cash generation and a shift toward shareholder returns after navigating post-COVID revenue normalization; sentiment improved among income-oriented and value investors while some others questioned whether buybacks were the best use of capital amid product headwinds. QIAGEN announced intent to seek shareholder approval to initiate a dividend and a new €500 million repurchase program in its Q1 2025 release (May 7, 2025) [11].

2025 Jun–Nov — Restructuring: NeuMoDx exit, plant closure and workforce reductions

QIAGEN decided to close its Ann Arbor (Michigan) PCR test manufacturing facility, exit the NeuMoDx business, and cut approximately 175 employees as part of a broader restructuring; the company estimated a pre-tax restructuring charge of about $400 million. The market viewed the actions as necessary portfolio rationalization to focus capital and management attention on higher-growth or higher-margin franchises (notably QuantiFERON and consumables). The scale of the charge and asset write-downs raised short-term earnings uncertainty, but some investors accepted the moves as value-preserving in the medium term. QIAGEN announced the shuttering of NeuMoDx, closure of the Ann Arbor facility, planned layoffs and an estimated pre-tax restructuring charge of approximately $400 million [14].

2025 Jun 26 — Supervisory board chair change

QIAGEN elected Stephen Rusckowski as Chairman of the Supervisory Board. Change in board leadership alongside the CEO succession process and strategic reshaping suggested governance renewal; investors monitoring board composition as a signal of potential strategic shifts or willingness to entertain strategic alternatives. Corporate press release announcing election of Stephen Rusckowski as Chairman of the Supervisory Board [7].

2024 Jul–Nov — Strategic review of NeuMoDx and initial signs of business rationalization

Management said it was considering "strategic options" for NeuMoDx in April and by mid-2024 had signalled possible divestiture or shutdown; discussions and decisions culminated in the later closure and restructuring actions. Investors began to see QIAGEN moving from pandemic-era scale decisions toward portfolio pruning and capital reallocation to higher-return franchises; this reinforced a narrative of active management but introduced execution and one-time charge risk. Company commentary in earnings calls and filings described strategic review of NeuMoDx and options including partner search or shutdown (April 2024 commentary summarized in reporting) [14].

2023 — Non-COVID growth rebound; QuantiFERON momentum; solid execution versus outlook

Throughout 2023 QIAGEN reported that non-COVID product sales grew in double digits at CER while COVID-product sales plunged; Q3 2023 sales of $470 million CER exceeded outlook and company reaffirmed FY 2023 outlook for net sales of at least $1.97–2.05 billion CER. QuantiFERON reached new annual sales milestones referenced in disclosures. Investor perception shifted to seeing QIAGEN as not dependent on COVID volumes, with a clearer "Pillars of Growth" message — QuantiFERON and consumables drove confidence that underlying franchise growth could support a recovery in organic sales. The stock narrative became a mixed growth story of recovery from COVID-revenue normalization rather than a COVID-era one-off beneficiary. Q3 2023 net sales $470 million CER; company initiated/reaffirmed FY 2023 outlook at about $2.05 billion CER; QuantiFERON cited as growing and breaking through annual sales milestones (company investor materials and Q3/Q1 releases) [16][18][21][22].

2022 Feb — Full-year 2021 results: non-COVID product growth and demonstration of balance

QIAGEN reported FY 2021 results showing strong non-COVID product performance (22% CER growth in the non-COVID portfolio for 2021) and results that exceeded outlook. The company aimed to demonstrate to investors that it was not dependent on COVID products and that its diversified Sample-to-Insight portfolio could drive sustainable growth; perception improved that management execution and the Five Pillars of Growth could produce durable revenue streams. Q4 2021 net sales $582 million (up 2% YoY; +4% CER); FY 2021 non-COVID product portfolio growth of 22% CER reported in the FY-2021 release/transcript [27][26].

2020–2021 (context carried into early 2021) — Aftermath of failed Thermo Fisher takeover

Although the Thermo Fisher unsolicited bid and its failure occurred in 2020, its effects continued to shape shareholder activism and strategic debate into 2021–2023. The failed acquisition kept QIAGEN in the spotlight among activists and strategic-options discussions; investors continued to debate whether the firm should remain independent and how management should allocate capital. That debate influenced perceptions of corporate governance and strategic flexibility during 2021–2023. Thermo Fisher's attempted acquisition failed when only approximately 47% of shares were tendered; QIAGEN paid a $95 million break fee per contemporaneous reporting (original news from 2020 but referenced in later commentary) [1][2][12].

2021 — Recovery and portfolio strength after COVID peak; QuantiFERON growth milestone

QIAGEN reported strong relative performance on non-COVID products through 2021 and reached QuantiFERON annual/cumulative sales milestones referenced in later 2022 disclosures. Investors began to accept the message that QIAGEN's consumables and diagnostics franchises (notably QuantiFERON) could sustain growth beyond pandemic demand, shifting views from a COVID-sensitive cyclical claimant toward a diversified diagnostics/growth company. Company reported QuantiFERON growth and milestones in subsequent 2022/2023 materials describing 2021 as the year the non-COVID portfolio achieved substantial growth (cited in company transcripts and annual reporting) [26][17].